Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a
larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs;
safety and efficacy data from clinical
studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
In addition, the LEAP
study design excluded 9.1 % of the infants who were screened (76 of 834) because
large wheals (greater than 4 mm in diameter) developed after the skin - prick test21 that were probably associated with peanut allergy; the
safety and effectiveness of early peanut consumption in that population remain unknown.
If sugar substitutes are used, such as aspartame or saccharin, consumers can be assured they have gone though
large scale
studies to validate
safety, and have gained approval from regulatory industries worldwide, including the Australian food regulator FSANZ.
The
study adds to the body of
large cohort
studies of planned home births that have reported on the relative
safety of home versus hospital births.
As far as we know, this is the
largest study into the
safety of home birth.
The most amazing epidemiological
study on the
safety of formula has been going on for decades, it's called «a
large proportion of full term humans in the developed world», and there is currently no hard data that there are dangers, or even visible trends associated with formula.
A new
study from the Family Online
Safety Institute (FOSI) reveals that the
large majority of parents believe technology has a positive effect on their child's future, career and life skills (78 %) and creativity (64 %).
In order to assess the efficiency and
safety of domperidone, researchers Catherine Paul et al. analyzed both the limited
studies available on maternal and infant exposure to the stimulant as well as
larger studies focused on its use in gastrointestinal disorder treatment.
Before trying this remedy for your baby's thrush, you should be aware of a recent
study raising concerns about the
safety of using gentian violet for treating thrush as it may cause cancer in animals if used in
large amounts.
Our
study adds to the body of
large cohort
studies of planned home births that have reported on the relative
safety of home versus hospital birth.
Washington, D.C. — A new
study from the Family Online
Safety Institute (FOSI) reveals that the
large majority of parents believe technology has a positive effect on their child's future, career and life skills (78 %) and creativity (64 %).
On the same day that Carmen Fariña was named the new schools chancellor — and said that school
safety had «improved by and
large» — the departing Bloomberg administration quietly released a two - year - old
study showing that nearly a third of LGBT students in city schools reported having been bullied.
«American effort reduced risky opioid prescriptions for veterans,
study finds: Reductions in highest doses through computer «dashboard» and prioritizing painkiller
safety suggests other
large health systems could do the same.»
Nonetheless, this July, the FDA suspended enrollment in Glaxo's
large clinical trial comparing the
safety of Avandia with that of a competing diabetes drug and may halt the
study altogether.
However,
safety concerns remain because
large scale effectiveness
studies are lacking.
The
largest urban health systems, which serve as
safety nets for
large patient populations with lower socioeconomic status and greater likelihood to speak English as a second language, do worse on government patient satisfaction scores than smaller, non-urban hospitals likely to serve white customers with higher education levels, according to a new
study by Mount Sinai researchers published this month in the Journal of Hospital Medicine.
According to Dunbar, the next logical step would be to take evinacumab into
larger clinical trials to
study its
safety, effectiveness, and optimal dosing.
Whereas the reasons for the effect remain unclear, a
large study led by Devanand suggests «
safety and nutritional issues associated with the loss of smell» — the inability to smell smoke, for example, and lack of interest in food from loss of taste — could be contributors.
For example, the results of one
study, known as UPLIFT, one of four
large - scale
studies conducted in 2008, demonstrated the effectiveness and
safety of a drug called Spirivain about 6,000 patients with respiratory disease.
Following the success of this preliminary
safety and feasibility
study, more patients are being recruited for a
larger clinical trial of the procedure to test the efficacy and durability of the procedure.
The
largest CBD
study presented efficacy and
safety data on GW Pharmaceutical's investigational medicine, Epidiolex (cannabidiol) from open - label Expanded Access programs at 16 sites.
Future pre-clinical work will require additional optimization,
large - scale mouse
studies and rigorous
safety analysis, the researchers emphasize.
«While Massachusetts
safety - net hospitals (many of which are minority - serving) received
large cuts in payments with the idea that other hospitals would assume the care of previously uninsured patients, this
study demonstrates the importance of securing the future of
safety - net and minority - serving hospitals through policy - based interventions to assure the continued care of vulnerable and underserved patient populations.»
Using data and follow - up from the first and
largest studies of TAVR
safety, the research team found that the biologic valves used in a TAVR procedure, as well as those used in open heart surgery, continue to perform well up to five years after implantation.
The team's next step will be to complete
studies showing
safety of SW033291 - related compounds in
larger animals, a required part of the pathway to secure approval from the U.S. Food and Drug Administration for trials in humans.
«Two years after the tragedy in Newtown, our
study of public support for two dozen specific gun policies found a
large majority of Americans continue to favor a range of gun -
safety policies,» says lead
study author Colleen Barry, PhD, MPP, an associate professor at the Johns Hopkins Bloomberg School of Public Health.
The drug has already demonstrated
safety in nonhuman primate trials, and the cardiovascular research might even be able to skip ahead to a
larger phase II trial based on
safety data from the ongoing phase I
studies, Leeper suggests.
It is one of the
largest studies to date to look at the
safety of ARV use during pregnancy.
Promising outcomes of preliminary
studies in patients in Southeast Asia and parts of Western and Central Africa led the World Health Organization to make the recommendation, but
safety and efficacy have not yet been proven in
large - scale clinical trials.
No
large - scale, long - term
studies have been conducted to examine the effectiveness and
safety of custom - compounded MHT.
Our
study is one of the
largest to explore the efficacy and
safety of anti-TNF therapy in a
large independent cohort of JDM patients.»
Strollo led a
large study of the new treatment, a yearlong
safety and efficacy trial involving 126 people with moderate to severe obstructive apnea.
«We're looking forward to longer - term results to come in the next five years from various ongoing observational
studies,» Dr. Arterburn said: The Utah Obesity
Study, the Michigan Bariatric Surgery Collaborative, and
large cohorts from Veterans Affairs health system and the HMO Research Network (including Group Health) and should yield important long - term information comparing the efficacy,
safety, and costs of surgical and non-surgical care for severe obesity.
The development track will begin with a Phase I trial to test the vaccine regimen's
safety and immunogenicity and depending on those
study results, a
larger efficacy
study will follow.
In a pilot
study, these investigators examined the
safety and feasibility of the protocol in a
large number of patients from different institutions, and identified predictors of the clinical response to the treatment.
There is a shortage of high - quality evidence demonstrating the
safety and effectiveness of long - term opioid therapy for the management of chronic pain, and to date, no
large - scale
studies have assessed strategies for managing and reducing chronic opioid use in real - world clinical settings.
As partner of TRANSVAC, IRTA will provide access to their animal facilities (CReSA) to carry out
safety and immunogenicity
studies of new candidate vaccines and / or of novel vaccination (administration) strategies in pigs, ferrets and other
large animal species.
The
study was the
largest yet focused on the
safety and efficacy of proactive antibiotic therapy to prevent infections in pediatric ALL patients during induction therapy.
In the meantime, some patients will continue to use marijuana even though
large studies havent tested its
safety and efficacy.
Researchers hope that if the ongoing preliminary
studies prove the
safety and effectiveness of these drugs for certain treatments, the government will step in to fund
larger trials.
The researchers added that
larger studies are also needed to evaluate the long - term
safety and effectiveness of the medication.
But according to the American Congress of Obstetricians and Gynecologists (ACOG), there have been no
large long - term clinical trials that have
studied the
safety and effectiveness of Bioidentical hormones.
«CHAMPAIGN, Ill. — Yerba maté tea - based beverages contained the
largest antioxidant and polyphenol content among tea - based and non-tea-based drink in a recent
study published in the Comprehensive Reviews in Food Science and Food
Safety (doi 10.1111/j.1541-4337.2010.00111.x).
The
large, ongoing French E3N
study is providing valuable
safety data for users of bioidentical hormones, most recently on estrogen, progesterone and the risk of stroke.
, «Yerba maté tea - based beverages contained the
largest antioxidant and poly - phenol content among tea - based and non-tea-based drink in a recent
study published in the Comprehensive Reviews in Food Science and Food
Safety.
There were also significant concerns about data tampering in the RECORD
study, one of the
largest trials that had «proved» its
safety.
A
large scale
study of the assessment of the social environment of middle and secondary schools: the validity and utility of teachers» ratings of school climate, cultural pluralism, and
safety problems for understanding school effects and school improvement.
Highest ranked
large light duty pickup in initial quality → Initial quality
study j.d. power cars → Car reviews & ratings, cars for sale j.d. power cars → 2017 j.d. power initial quality rankings automotive news → Chevy reviews, awards, &
safety information chevrolet → New chevys for sale in el paso preowned chevys near las → Today's stock market news and analysis nasdaq → Used 2017 chevrolet silverado 1500 ltz near mount laurel → Toyota tundra wikipedia → Business news, personal finance and money news abc news →
Highest ranked
large suv in initial quality fullsize → Highest ranked
large light duty pickup in initial quality → Vehicle dependability
study ratings, articles, and reviews → Chevy reviews, awards, &
safety information chevrolet → Car & auto news cars → Lexus lx wikipedia → Ford expedition wikipedia → Today's stock market news and analysis nasdaq → Business news, personal finance and money news abc news → Autoblog new cars, used cars for sale, car reviews and news →
Source: EdmundsAwards: * JD Power Initial Quality
Study * 2016 IIHS Top
Safety Pick with optional front crash prevention * 2016 IIHS Top
Safety PickMoran Buick GMC is the newest addition to the Moran Automotive Group which includes the nations
largest volume Chevrolet dealer.